Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet — Clinical Trial Site

81 Registered trials

25 Currently recruiting

Organisation

Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet

Location

Szolnok, Hungary

Identifier

ORG-100041273

Address

Toszegi Ut 21, 5000, Hungary

Departments

348005: Mozgasszervi Centrum Ortopediai Osztalya
7812: Kardiológiai Osztály
Cardiology Department
County Oncology Center
Department of Oncology
Endocrinology
Endocrinology and Internal Medicine
III Belgyógyászati Osztály
Kardiologia
Kardiologiai Osztaly
Megyei Onkológiai Központ
Megyei Onkológiai Centrum
Megyei Onkológiai Centrum (Department of Oncology)
Megyei Onkológiai Központ
N/A
NA
Neurology Department
Oncology
Onkológiai Központ
Onkologiai Osztaly
Pulmonológia
Pulmonologiai Osztaly
Tüdőgyógyászati osztály
Vármegyei Onkológia Központ
Varmegyei Onkologiai Kozpont

Clinical trials at this site (81)

Search interface

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Ended

2025-523974-18-00 Obesity 5 2026-04-30
A Study to Compare Different Doses of RO7795081 with a Placebo or Semaglutide in People with Type 2 Diabetes Ended

2024-520322-11-00 Type 2 Diabetes Mellitus (T2D) 4 2025-09-29
A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended

2025-520521-21-00 Hyperlipidemia 5 2025-09-02
A clinical study of pembrolizumab and other treatments for non-small cell lung cancer (MK-3475-01G) Ended

2024-515772-12-00 Lung neoplasm malignant (Stage IV Non-small cell lung c 4 2025-04-18
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
Clinical Study of Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) versus Intravenous Pembrolizumab, Given with Chemoth… Ended

2022-501506-36-00 First-line treatment of participants with metastatic no 5 2023-04-11
A Study of Dato-DXd in Combination With Durvalumab and Carboplatin for First-line Treatment of Advanced NSCLC Without Actionable Genomic Alt… Ended

2023-505993-14-00 Non-Small Cell Lung Cancer (NSCLC) 5 2023-01-05
A trial to learn how well capivasertib with docetaxel works and how safe it is in people with metastatic castration-resistant prostate cance… Ended

2023-504996-26-00 Metastatic Castration Resistant Prostate Cancer (mCRPC) 5 2022-07-21
A study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-s… Ended

2023-503868-16-00 Small-Cell Lung Cancer (SCLC) 5 2022-02-14
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca… Ended

2023-509631-37-00 "Inoperable or Metastatic Hormone Receptor-Positive, HE 5 2022-01-18
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec… Ended

2024-512038-13-00 Metastatic or unresectable locally advanced BRAF V600E/ 5 2021-09-16
A clinical study of pembrolizumab with other study treatments in people with refractory lung cancer (MK-3475-B98) Ended

2023-507687-38-00 Participants with extensive-stage small cell lung cance 9 2021-08-23
A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended

2022-502100-70-00 Participants with Microsatellite Instability-High (MSI- 10 2021-06-23
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive… Ended

2023-505249-24-00 HER2-positive metastatic breast cancer 5 2021-05-27
An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended

2022-502122-41-00 Clear cell renal cancer 5 2021-05-11
Phase 3 Trial of Perioperative EV and Pembro vs. Chemo in Cis-E MIBC Ended

2023-505615-21-00 Muscle Invasive Bladder Cancer 5 2021-04-28
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat… Ended

2023-507338-26-00 Histologically documented gastric or gastroesophageal j 5 2021-02-01
Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca… Ended

2024-516653-44-00 HER2-Low, Hormone Receptor Positive Breast Cancer which 5 2020-11-30
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in… Ended

2023-505812-39-00 HR+/HER2-Negative Locally Advanced or Metastatic Breast 5 2020-08-28